Home LiteratureArticle Details
PMID: 16510760 Published · ppublish English Case Reports Letter

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

The New England journal of medicine ·Vol. 354 ·No. 9 ·2006-03-02 ·Pages 980-2; discussion 980-2

Glusker P, Recht L, Lane B

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal/adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Brain/pathology Female Humans Hypertensive Encephalopathy/chemically induced,pathology Kidney Neoplasms/drug therapy Magnetic Resonance Imaging Middle Aged Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Vascular Endothelial Growth Factor A Bevacizumab
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Glusker Peter
Recht Larry
Lane Barton
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMc052954
Published
2006-03-02
Pages
980-2; discussion 980-2
Language
English
Region
United States
NLM ID
0255562
Subset
IM
External Links
PubMed source DOI: 10.1056/NEJMc052954 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2